Contact Us
Contact Us

Use Case: Robust, Futureproof, IP Protection in Biotech

Your IP is one of your company’s most valuable assets and the way you protect it should reflect that. Read on to explore how ZONTAL has helped leading pharma and biotech companies achieve IP security.

In the past, paper notebooks written with ink were used by scientists. Today, electronic lab notebooks (ELN) are the common choice, however most ELNs do not provide an option to create digital signatures for their records. It is also common for large biotechs to have multiple different ELN systems in place. Without additional measures, ELN entries might not be able to provide necessary evidence in court.

By implementing ZONTAL, leading biotech companies are able to save time and money, whilst protecting their reputation and maintaining regulatory compliance. 

Complete the form below to download the full use case.





Related Posts

The Future of the Digital Lab at Novartis with ZONTAL

At the 2020 Fall Allotrope Connect, Novartis discussed the implementation of their new data...

Systems in Laboratories - Replacement / Decommissioning / Harmonization

Many of our customers have legacy systems in their infrastructure that need to be decommissioned...

Webinar:  Integrated Sample Analysis

IDBS (e-Workbook), AGU (SDC), and ZONTAL (FAIR Data Hub), demonstrate end-to-end sample workflow